文献速递核素与放射性配体治疗肿瘤 PET/CT

一例同时患前列腺癌与肾细胞癌患者的177镥-PSMA治疗

177 Lutetium-PSMA Therapy in a Patient With Concurrent Prostate Cancer and Renal Cell Carcinoma.
PubMed 文献 · Clin Nucl Med · 2025-06-10

77岁转移性前列腺癌男性,抗雄激素治疗后骨痛严重、PSA升高,68Ga-PSMA PET/CT显示广泛PSMA阳性骨转移及偶发PSMA高摄取肾肿块,后者确诊为肾细胞癌。患者接受四周期177Lu-PSMA-617,骨痛完全缓解、骨转移明显改善、PSA下降,但肾肿块未见变化;177Lu-PSMA-617对肾细胞癌未见显著治疗效应。

要点

  • 77岁转移性前列腺癌患者接受四周期177Lu-PSMA-617后骨痛完全缓解、骨转移明显改善、PSA下降。
  • 68Ga-PSMA PET/CT偶发PSMA高摄取肾肿块,后确诊为肾细胞癌。
  • 177Lu-PSMA-617对肾细胞癌未见显著治疗效应,肾肿块未见变化。

核心结论

  • 177Lu-PSMA-617对转移性前列腺癌产生骨痛完全缓解、骨转移明显改善和PSA下降,但对并发的肾细胞癌未见显著治疗效应。
  • 177Lu-PSMA治疗在非前列腺恶性肿瘤中的疗效仍在研究中。

研究设计与样本

  • 本文为单例病例报告,患者为77岁转移性前列腺癌男性。

主要发现

  • 患者抗雄激素治疗后仍骨痛严重、PSA升高,68Ga-PSMA PET/CT显示广泛PSMA阳性骨转移及偶发PSMA高摄取肾肿块。
  • 肾肿块 later 确诊为肾细胞癌。
  • 患者接受四周期177Lu-PSMA-617后骨痛完全缓解、骨转移明显改善、PSA下降,肾肿块未见变化。
  • 177Lu-PSMA-617对肾细胞癌未见显著治疗效应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 77-year-old man with metastatic prostate cancer presented with debilitating bone pain and rising PSA despite anti-androgen therapy. 68 Ga-PSMA PET/CT scan revealed widespread PSMA-positive bone metastases with an incidental PSMA-avid renal mass, later confirmed as renal cell carcinoma (RCC). The patient received four cycles of 177 Lu-PSMA-617, which resulted in complete pain resolution, marked improvement in bone metastases, and PSA reduction; while no change in the renal mass is noted. Despite the beneficial effects of 177 Lu-PSMA therapy in metastatic prostate cancer, its efficacy in nonprostatic malignancies is under investigation. In this case, 177 Lu-PSMA-617 did not show remarkable therapeutic efficiency in RCC.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Albooyeh H, Amini H, Arefnia M, et al. 177 Lutetium-PSMA Therapy in a Patient With Concurrent Prostate Cancer and Renal Cell Carcinoma. Clin Nucl Med. 2025. PMID: 40494366. doi:10.1097/RLU.0000000000005964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。